{
  "patent_number": "US 8592397",
  "country": "US",
  "title": "How Gilead Made a Stable HIV Pill Combining Two Medicines",
  "original_title": "Compositions and methods for combination antiviral therapy",
  "summary": "This patent describes a stable, single-pill combination of two HIV drugs, tenofovir disoproxil fumarate and emtricitabine, designed to prevent them from breaking down when stored together.",
  "what_it_does": "The patent claims a specific pharmaceutical recipe that combines 300 mg of tenofovir disoproxil fumarate and 200 mg of emtricitabine into one oral pill. Because these two chemicals are chemically incompatible and tend to degrade when mixed, the patent specifies a precise blend of binders, disintegrants, and lubricants—such as pregelatinized starch and magnesium stearate—to stabilize the mixture. This ensures the pill remains effective for at least six months, even under high-heat and high-humidity conditions, by preventing the active ingredients from breaking down into inactive or harmful components.",
  "what_it_does_not_cover": [
    "Does not cover the individual chemical structures of tenofovir disoproxil fumarate or emtricitabine themselves.",
    "Does not cover combinations of these drugs with other active ingredients not specified in the claims.",
    "Does not cover dosage forms that do not meet the specific stability requirement of less than 10% degradation over 6 months at 40 degrees Celsius.",
    "Does not cover liquid or injectable versions of these drugs."
  ],
  "filed": "2008-08-20",
  "granted": "2013-11-26",
  "expires": null,
  "status": "active",
  "holder": "Gilead Sciences Inc",
  "holder_url": "https://patentbrief.org/company/gilead-sciences-inc",
  "inventors": [
    {
      "name": "Reza Oliyai",
      "url": "https://patentbrief.org/inventor/reza-oliyai"
    },
    {
      "name": "Terrence C. Dahl",
      "url": "https://patentbrief.org/inventor/terrence-c-dahl"
    },
    {
      "name": "Mark M. Menning",
      "url": "https://patentbrief.org/inventor/mark-m-menning"
    }
  ],
  "times_cited": 19,
  "tags": [
    "biotech",
    "pharmaceutical"
  ],
  "abstract": "The present invention relates to therapeutic combinations of [2-(6-amino-purin-9-yl)-1-methyl-ethoxymethyl]-phosphonic acid diisopropoxycarbonyloxymethyl ester (tenofovir disoproxil fumarate, Viread®) and (2R, 5S, cis)-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one(emtricitabine, Emtriva™, (-)-cis FTC) and their physiologically functional derivatives. The combinations may be useful in the treatment of HIV infections, including infections with HIV mutants bearing resistance to nucleoside and/or non-nucleoside inhibitors. The present invention is also concerned with pharmaceutical compositions and formulations of said combinations of tenofovir disoproxil fumarate and emtricitabine, and their physiologically functional derivatives, as well as therapeutic methods of use of those compositions and formulations.",
  "url": "https://patentbrief.org/patent/us/8592397/truvada-tdf-ftc-for-prep",
  "markdown_url": "https://patentbrief.org/patent/us/8592397/truvada-tdf-ftc-for-prep/md",
  "google_patents_url": "https://patents.google.com/patent/US8592397",
  "relatedPatents": []
}